O	0	10	Randomized
O	11	16	study
O	17	19	of
O	20	26	orally
O	27	39	administered
O	40	51	fluorinated
O	52	63	pyrimidines
O	64	65	(
B-intervention	65	77	capecitabine
O	78	84	versus
B-control	85	86	S
I-control	86	87	-
I-control	87	88	1
O	88	89	)
O	90	92	in
O	93	98	women
O	99	103	with
O	104	114	metastatic
O	115	117	or
O	118	127	recurrent
O	128	134	breast
O	135	141	cancer
O	141	142	:
O	143	148	Japan
O	149	155	Breast
O	156	162	Cancer
O	163	171	Research
O	172	179	Network
O	180	182	05
O	183	188	Trial
O	188	189	.

O	190	202	Capecitabine
O	203	206	and
O	207	208	S
O	208	209	-
O	209	210	1
O	211	214	are
O	215	221	orally
O	222	234	administered
O	235	246	fluorinated
O	247	258	pyrimidines
O	259	263	with
O	264	268	high
O	268	269	-
O	269	274	level
O	275	283	activity
O	284	291	against
O	292	302	metastatic
O	303	309	breast
O	310	316	cancer
O	317	318	(
O	318	321	MBC
O	321	322	)
O	322	323	.

O	324	328	This
O	329	339	randomized
O	339	340	,
O	341	352	multicenter
O	352	353	,
O	354	359	phase
O	360	362	II
O	363	368	study
O	369	377	compared
O	378	381	the
O	382	392	activities
O	393	396	and
O	397	405	safeties
O	406	408	of
O	409	412	the
O	413	417	oral
O	418	435	fluoropyrimidines
O	435	436	,
O	437	449	capecitabine
O	450	453	and
O	454	455	S
O	455	456	-
O	456	457	1
O	457	458	,
O	459	461	in
O	462	468	breast
O	469	475	cancer
O	476	484	patients
O	484	485	.

B-eligibility	486	494	Patients
I-eligibility	495	499	with
I-eligibility	500	503	MBC
O	504	508	were
O	509	517	randomly
O	518	526	assigned
O	527	529	to
O	530	537	receive
O	538	550	capecitabine
O	551	554	825
O	555	556	g
O	556	557	/
O	557	558	m
O	558	559	(
O	559	560	2
O	560	561	)
O	562	567	twice
O	568	573	daily
O	574	576	on
O	577	581	days
O	582	583	1
O	583	584	-
O	584	586	21
O	587	592	every
O	593	594	4
O	595	600	weeks
O	601	603	or
O	604	605	S
O	605	606	-
O	606	607	1
O	608	610	40
O	610	611	-
O	611	613	60
O	614	616	mg
O	617	622	twice
O	623	628	daily
O	628	629	,
O	630	639	according
O	640	642	to
O	643	647	body
O	648	655	surface
O	656	660	area
O	660	661	,
O	662	664	on
O	665	669	days
O	670	671	1
O	671	672	-
O	672	674	28
O	675	680	every
O	681	682	6
O	683	688	weeks
O	688	689	.

O	690	693	The
O	694	701	primary
O	702	710	endpoint
O	711	714	was
B-outcome-Measure	715	726	progression
I-outcome-Measure	726	727	-
I-outcome-Measure	727	731	free
I-outcome-Measure	732	740	survival
I-outcome-Measure	741	742	(
I-outcome-Measure	742	745	PFS
I-outcome-Measure	745	746	)
O	746	747	.

O	748	749	A
O	750	755	total
O	756	758	of
B-total-participants	759	762	142
O	763	771	patients
O	772	776	were
O	777	785	enrolled
O	786	789	and
O	790	800	randomized
O	801	803	to
O	804	810	either
O	811	823	capecitabine
O	824	825	(
O	825	826	N
O	827	828	=
B-intervention-participants	829	831	73
O	831	832	)
O	833	835	or
O	836	837	S
O	837	838	-
O	838	839	1
O	840	841	(
O	841	842	N
O	843	844	=
B-control-participants	845	847	69
O	847	848	)
O	848	849	.

B-outcome	850	856	Median
I-outcome	857	860	PFS
O	861	862	(
O	862	873	progression
O	873	874	-
O	874	878	free
O	879	887	survival
O	887	888	)
O	889	892	was
B-iv-cont-median	893	894	1
I-iv-cont-median	894	895	.
I-iv-cont-median	895	896	2
I-iv-cont-median	897	902	years
O	903	906	for
O	907	919	capecitabine
O	920	923	and
B-cv-cont-median	924	925	1
I-cv-cont-median	925	926	.
I-cv-cont-median	926	927	3
I-cv-cont-median	928	933	years
O	934	937	for
O	938	939	S
O	939	940	-
O	940	941	1
O	941	942	,
O	943	947	with
O	948	949	a
O	950	956	hazard
O	957	962	ratio
O	963	964	(
O	964	965	S
O	965	966	-
O	966	967	1
O	967	968	/
O	968	980	capecitabine
O	980	981	)
O	982	984	of
O	985	986	0
O	986	987	.
O	987	989	85
O	990	991	(
O	991	993	95
O	994	995	%
O	996	1006	confidence
O	1007	1015	interval
O	1016	1017	[
O	1017	1019	CI
O	1019	1020	]
O	1021	1022	0
O	1022	1023	.
O	1023	1025	52
O	1025	1026	-
O	1026	1027	1
O	1027	1028	.
O	1028	1030	38
O	1030	1031	)
O	1032	1033	(
O	1033	1034	P
O	1035	1036	=
O	1037	1038	0
O	1038	1039	.
O	1039	1041	48
O	1042	1044	by
O	1045	1048	log
O	1048	1049	-
O	1049	1053	rank
O	1053	1054	)
O	1054	1055	.

O	1056	1059	The
O	1060	1069	confirmed
B-outcome	1070	1079	objective
I-outcome	1080	1088	response
I-outcome	1089	1094	rates
O	1095	1099	were
B-iv-bin-percent	1100	1102	24
I-iv-bin-percent	1102	1103	.
I-iv-bin-percent	1103	1104	0
I-iv-bin-percent	1105	1106	%
O	1107	1110	for
O	1111	1123	capecitabine
O	1124	1127	and
B-cv-bin-percent	1128	1130	23
I-cv-bin-percent	1130	1131	.
I-cv-bin-percent	1131	1132	1
I-cv-bin-percent	1133	1134	%
O	1135	1138	for
O	1139	1140	S
O	1140	1141	-
O	1141	1142	1
O	1143	1144	(
O	1144	1145	P
O	1146	1147	=
O	1148	1149	0
O	1149	1150	.
O	1150	1153	938
O	1153	1154	)
O	1154	1155	.

O	1156	1159	The
O	1160	1164	most
O	1165	1171	common
B-outcome	1172	1181	treatment
I-outcome	1181	1182	-
I-outcome	1182	1189	related
I-outcome	1190	1197	adverse
I-outcome	1198	1204	events
O	1205	1209	were
O	1210	1215	grade
O	1216	1217	1
O	1217	1218	-
O	1218	1219	2
O	1220	1222	in
O	1223	1232	intensity
O	1232	1233	.

B-outcome	1234	1250	Thrombocytopenia
O	1251	1252	(
O	1252	1253	S
O	1253	1254	-
O	1254	1255	1
O	1255	1256	:
B-cv-bin-percent	1257	1258	9
I-cv-bin-percent	1258	1259	.
I-cv-bin-percent	1259	1260	2
I-cv-bin-percent	1261	1262	%
O	1262	1263	,
O	1264	1276	capecitabine
O	1276	1277	:
B-iv-bin-percent	1278	1279	1
I-iv-bin-percent	1279	1280	.
I-iv-bin-percent	1280	1281	4
I-iv-bin-percent	1282	1283	%
O	1283	1284	;
O	1285	1286	P
O	1287	1288	=
O	1289	1290	0
O	1290	1291	.
O	1291	1294	040
O	1294	1295	)
O	1296	1299	and
B-outcome	1300	1306	nausea
O	1307	1308	(
O	1308	1309	S
O	1309	1310	-
O	1310	1311	1
O	1311	1312	:
B-cv-bin-percent	1313	1315	26
I-cv-bin-percent	1315	1316	.
I-cv-bin-percent	1316	1317	2
I-cv-bin-percent	1318	1319	%
O	1319	1320	,
O	1321	1333	capecitabine
O	1333	1334	:
B-iv-bin-percent	1335	1337	14
I-iv-bin-percent	1337	1338	.
I-iv-bin-percent	1338	1339	1
I-iv-bin-percent	1340	1341	%
O	1341	1342	;
O	1343	1344	P
O	1345	1346	=
O	1347	1348	0
O	1348	1349	.
O	1349	1352	079
O	1352	1353	)
O	1354	1358	were
O	1359	1363	more
O	1364	1372	frequent
O	1373	1375	in
O	1376	1379	the
O	1380	1381	S
O	1381	1382	-
O	1382	1383	1
O	1384	1389	group
O	1389	1390	,
O	1391	1396	while
B-outcome	1397	1401	hand
I-outcome	1401	1402	-
I-outcome	1402	1406	foot
I-outcome	1407	1415	syndrome
O	1416	1424	occurred
O	1425	1429	more
O	1430	1435	often
O	1436	1438	in
O	1439	1442	the
O	1443	1455	capecitabine
O	1456	1461	group
O	1462	1463	(
O	1463	1464	S
O	1464	1465	-
O	1465	1466	1
O	1466	1467	:
B-cv-bin-percent	1468	1470	10
I-cv-bin-percent	1470	1471	.
I-cv-bin-percent	1471	1472	8
I-cv-bin-percent	1473	1474	%
O	1474	1475	,
O	1476	1488	capecitabine
O	1488	1489	:
B-iv-bin-percent	1490	1492	25
I-iv-bin-percent	1492	1493	.
I-iv-bin-percent	1493	1494	4
I-iv-bin-percent	1495	1496	%
O	1496	1497	;
O	1498	1499	P
O	1500	1501	=
O	1502	1503	0
O	1503	1504	.
O	1504	1507	029
O	1507	1508	)
O	1508	1509	.

O	1510	1513	The
O	1514	1521	results
O	1522	1524	of
O	1525	1528	the
O	1529	1536	current
O	1537	1542	study
O	1543	1554	demonstrate
O	1555	1559	that
O	1560	1564	both
O	1565	1566	S
O	1566	1567	-
O	1567	1568	1
O	1569	1572	and
O	1573	1585	capecitabine
O	1586	1589	are
O	1590	1599	effective
O	1600	1603	and
O	1604	1608	well
O	1608	1609	-
O	1609	1618	tolerated
O	1619	1629	treatments
O	1630	1632	in
O	1633	1641	patients
O	1642	1646	with
O	1647	1650	MBC
O	1650	1651	,
O	1652	1657	while
O	1658	1663	their
O	1664	1671	adverse
O	1672	1678	events
O	1679	1683	were
O	1684	1693	different
O	1693	1694	.

O	1695	1699	They
O	1700	1703	are
O	1704	1708	both
O	1709	1719	convenient
O	1719	1720	,
O	1721	1727	orally
O	1728	1740	administered
O	1741	1746	drugs
O	1746	1747	,
O	1748	1754	making
O	1755	1759	them
O	1760	1770	attractive
O	1771	1777	agents
O	1778	1781	for
O	1782	1785	use
O	1786	1788	in
O	1789	1799	outpatient
O	1800	1809	treatment
O	1809	1810	.
